Flat sales, firmer margins

EKF Diagnostics Holdings plc (LSE:EKF) reported interim results on 15 September 2026 showing broadly flat revenue but a meaningful improvement in gross margin, as the point-of-care and life sciences group continues a five-year growth plan. Revenue for the six months to 30 June 2026 was £25.0 million, against £25.2 million a year earlier, while gross margin rose to 53.0% from 50.2%. Management said it expects full-year revenue and adjusted EBITDA growth in line with market expectations.

What the company does

EKF is a diagnostics business that makes point-of-care analysers and consumables, notably for haematology testing such as haemoglobin measurement, alongside a life sciences operation that provides contract manufacturing and fermentation services. It also produces beta-hydroxybutyrate (β-HB) reagents used in ketone testing. The life sciences services arm has recently been rebranded as Nexus Bioworks.

Latest developments

The interim period featured several operational steps. EKF exited its Elkhart, Indiana site early, acquired technology from BEEP Insights, and expanded Hemo Control consumables capacity by a further 30%. The group's strategy rests on three pillars: growing contract manufacturing and fermentation, expanding β-HB revenues, and accelerating point-of-care growth in haematology.

Chief executive Gavin Jones described the half as a testament to the resilience of a diversified portfolio. The company said most of the delayed point-of-care revenue is expected in the second half, supported by existing orders, and expressed confidence that point-of-care haematology would return to growth in the second half of 2026.

Financial picture

Adjusted EBITDA rose 2.4% to £5.9 million, while operating profit eased to £3.3 million from £3.6 million and profit before tax was £3.4 million. Profit attributable to owners increased to £2.3 million, with basic earnings per share of 0.54p. Cash stood at £16.0 million at 30 June 2026, including £2.4 million held in Russia that is subject to transfer restrictions. Free cash flow fell to £1.1 million, reflecting capital expenditure and tax timing.

Net cash from operations was £3.3 million, down from £4.9 million. No dividend was declared for the period. Instead, EKF returned capital through share buybacks, repurchasing 3.55 million shares for £0.9 million. The company cited consensus forecasts of £54.6 million of revenue and £13.6 million of adjusted EBITDA for 2026, and reiterated its ambition of more than £80 million of revenue and £20 million of adjusted EBITDA by 2029.

Sector and index context

EKF is one of a number of healthcare and diagnostics names within the FTSE AIM All Share Index. The sector has been working through a normalisation of demand since the pandemic-era testing boom, with investors increasingly focused on recurring consumables revenue, margins and cash generation rather than one-off volume spikes. EKF's shift towards higher-margin contract manufacturing and fermentation reflects that broader emphasis.

Key risks

Revenue timing in point-of-care haematology has already slipped once, and further delays could weigh on second-half delivery. The group's 2029 targets imply substantial growth from current levels, requiring successful execution across all three strategic pillars. Restricted cash in Russia, exposure to international markets and currency movements, and dependence on capacity expansion projects are further risks.

What to watch next

The key test will be whether second-half trading delivers the delayed point-of-care revenue and keeps the full year in line with consensus. Investors will also watch for progress in contract manufacturing and fermentation, the commercial contribution from the newly branded Nexus Bioworks, any extension of buyback activity, and a full-year trading update in early 2027.